Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Invested Capital (2017 - 2025)

Protagonist Therapeutics' Invested Capital history spans 9 years, with the latest figure at $614.7 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 8.97% year-over-year to $614.7 million; the TTM value through Dec 2025 reached $614.7 million, down 8.97%, while the annual FY2025 figure was $614.7 million, 8.97% down from the prior year.
  • Invested Capital for Q4 2025 was $614.7 million at Protagonist Therapeutics, down from $645.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $689.1 million in Q1 2025 and bottomed at $215.6 million in Q4 2022.
  • The 5-year median for Invested Capital is $333.2 million (2021), against an average of $417.6 million.
  • The largest annual shift saw Invested Capital skyrocketed 256.88% in 2021 before it decreased 28.45% in 2023.
  • A 5-year view of Invested Capital shows it stood at $300.0 million in 2021, then decreased by 28.14% to $215.6 million in 2022, then skyrocketed by 56.15% to $336.7 million in 2023, then surged by 100.58% to $675.3 million in 2024, then decreased by 8.97% to $614.7 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Invested Capital are $614.7 million (Q4 2025), $645.4 million (Q3 2025), and $668.0 million (Q2 2025).